With the numbers of the drugs in the pipeline, the gene therapy market is entering an era of innovative treatment options for those affected by bleeding disorders. Owing to the innovation made in the treatment there progress and technology advancement Haemophilia gene therapy is soon expected to be a possibility. Haemophilia is one disease which is expected to be a target for treatment with haemophilia gene therapy. Even though there is no current commercial gene therapy treatment available in the market, it is soon expected to be in reality. Number of companies such as Biomarine pharmaceutical, Spark therapeutics (acquired by Roche), Pfizer are in race to bring their drug in the market. Trailed by Roche it Roche diagnostics, Biomarine pharmaceutical is likely to in the race of bringing their molecule first the market and is likely to enter in the market in the year 2020.
The key factor that is contributing to the growth of the market include, the increasing number of people suffering from the hemophillia along with the increasing population. As indicated by National Institute Of Hemophilia, around 20,000 people in U.S. and 400,000 globally are suffering from haemophilia. Moreover the government of various countries are supporting the funds for the research and development purpose. For instance, The National hemophilia foundation is awarding grants to further support the research for Hemophilia Gene therapy which will in turn help in the treatment of hemophilia. Such initiatives from the government are likely to support the growth of the market over the forecast period.
Availability of limited treatment therapy options and growing burden on the regulatory bodies towards its treatment results is expected to boost the growth of the market
The report analyses the hemophillia gene therapy market on the basis of type, vactors and geography.
On the basis of type, the market is segmented into hemophilia type A and hemophillia type B. Hemophillia type A is observed to be the most frequent type and has been recorded to be four times more prevalent than Hemophilia type B. Moreover, the products that are ready to be introduced in the market are targeted to Hemopillia type A. However, type B is anticipated to be the fastest growing segment over the forecast period due to presence of strong pipeline products.
Hemophilia gene therapy market by Vectors is classified into vector A and vector B. Although the current trends in hemophilia using adeno-associated viral vectors are safe but also involve immunogenicity problems. The other alternatives as non-viral vectors are on rise. The breakout of viral and non-viral offers the forecast of changing trend of gene transfer technique till 2030
Based on geography, the global hemophilia gene therapy market market is segmented into North America, Europe, Asia Pacific and Rest of the World. North America is likely to grab the major share of the market owing to the increasing prevalence hemophilia coupled with growing inclination towards advanced treatment is likely to be the preliminary drivers of regional growth.
The key competitors of this market include BioMarin Pharmaceuticals, Bioverativ, Uniqure NV, Sangmo Therapeutics, Spark Therapeutics, Shire PlC, Ultragenyx Pharmaceuticals, Freeline Therapeutics and among others.
The report analyses the global hemophilia gene therapy market based on hemophilia type, vectors and geography. By hemophilia type, the market is segmented into hemophilia A and hemophilia B. based on vectors, the market is segmented into non-viral and viral. The global hemophilia gene therapy market is studied across various key countries of regions such as, North America, Europe, Asia Pacific and Rest Of the World.
Why to buy this report: